Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

doi:10.1093/annonc/mdy025

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2018

Hartmaier R J, Trabucco S E, Priedigkeit N, Chung J H, Parachoniak C A, Vanden Borre P, Morley S, Rosenzweig M, Gay L M, Goldberg M E, Suh J, Ali S M, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan R D, Sachelarie I, Cho J, Atkinson J M, Bahreini A, Nagle A M, Puhalla S L, Watters R J, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas P C, Davidson N E, Brufsky A M, Frampton G M, Stephens P J, Chmielecki J, Lee A V

Abstract excerpt

Background: Estrogen receptor-positive (ER-positive) metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching events have been associated with endocrine-therapy resistance, recurrent ESR1 fusion proteins have yet to be identified in advanced breast cancer. Patients and methods: To identify genomic structural rearrangements (REs) including gene fusions in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Drug Resistance, Neoplasm

Share to Estrogen Receptor alpha

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasm Metastasis

Share to Recombinant Fusion Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 29360925
DOI: 10.1093/annonc/mdy025
PMCID: PMC5913625

Genes

ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.PMID 29360925Read ↗

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read ↗

Molecular characterization of ESR1 variants in breast cancer.Semantic proximity Read ↗

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.Semantic proximity Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Semantic proximity Read ↗

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.Semantic proximity Read ↗

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrencesSemantic proximity Read ↗

Estrogen receptor mutations and their role in breast cancer progression.Semantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

<i>ESR1</i> fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypesSemantic proximity Read ↗

ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.Semantic proximity Read ↗

Molecular Characterization of ESR1 Variants in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.